RRAD and glioblastoma: Accumulating evidence suggests that the RRAD promoter is hypermethylated in human cancers, such as nasopharyngeal carcinoma [17,18], breast cancer [26], esophageal cancer [30], glioblastoma [42], cervical carcinoma [28], ovary cancer [27,31], and lung cancer [24,26].